Redox homeostasis is tightly controlled and regulates key cellular signaling pathways. The cell's antioxidant response provides a natural defense against oxidative stress, but excessive antioxidant generation leads to reductive stress (RS). This study elucidated how chronic RS, caused by constitutive activation of nuclear erythroid related factor-2 (caNrf2)-dependent antioxidant system, drives pathological myocardial remodeling.
Results:
Upregulation of antioxidant transcripts and proteins in caNrf2-TG hearts (TGL and TGH; transgenic-low and -high) dose dependently increased glutathione (GSH) redox potential and resulted in RS, which over time caused pathological cardiac remodeling identified as hypertrophic cardiomyopathy (HCM) with abnormally increased ejection fraction and diastolic dysfunction in TGH mice at 6 months of age. While the TGH mice exhibited 60% mortality at 18 months of age, the rate of survival in TGL was comparable with nontransgenic (NTG) littermates. Moreover, TGH mice had severe cardiac remodeling at ∼6 months of age, while TGL mice did not develop comparable phenotypes until 15 months, suggesting that even moderate RS may lead to irreversible damages of the heart over time. Pharmacologically blocking GSH biosynthesis using BSO (l-buthionine-SR-sulfoximine) at an early age (∼1.5 months) prevented RS and rescued the TGH mice from pathological cardiac remodeling. Here we demonstrate that chronic RS causes pathological cardiomyopathy with diastolic dysfunction in mice due to sustained activation of antioxidant signaling.
Innovation and Conclusion:
Our findings demonstrate that chronic RS is intolerable and adequate to induce heart failure (HF). Antioxidant-based therapeutic approaches for human HF should consider a thorough evaluation of redox state before the treatment.
Get full access to this article
View all access options for this article.
References
1.
AgoT, LiuT, ZhaiP, ChenW, LiH, MolkentinJD, VatnerSF, and SadoshimaJ. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell, 133: 978–993, 2008.
2.
Al-KhudairyL, FlowersN, WheelhouseR, GhannamO, HartleyL, StrangesS, and ReesK. Vitamin C supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 3: CD011114, 2017.
3.
BairatiI, MeyerF, JobinE, GelinasM, FortinA, NabidA, BrochetF, and TetuB. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer, 119: 2221–2224, 2006.
4.
BansalD, BhallaA, BhasinDK, PandhiP, SharmaN, RanaS, and MalhotraS. Safety and efficacy of vitamin-based antioxidant therapy in patients with severe acute pancreatitis: a randomized controlled trial. Saudi J Gastroenterol, 17: 174–179, 2011.
5.
BhuiyanT and MaurerMS. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep, 5: 440–449, 2011.
6.
BjelakovicG, NikolovaD, GluudLL, SimonettiRG, and GluudC. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA, 297: 842–857, 2007.
7.
BorlaugBA and PaulusWJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J, 32: 670–679, 2011.
8.
BrewerAC, MustafiSB, MurrayTV, RajasekaranNS, and BenjaminIJ. Reductive stress linked to small HSPs, G6PD, and Nrf2 pathways in heart disease. Antioxid Redox Signal, 18: 1114–1127, 2013.
9.
BrianconS, BoiniS, BertraisS, GuilleminF, GalanP, and HercbergS. Long-term antioxidant supplementation has no effect on health-related quality of life: the randomized, double-blind, placebo-controlled, primary prevention SU.VI.MAX trial. Int J Epidemiol, 40: 1605–1616, 2011.
10.
BuiAL, HorwichTB, and FonarowGC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol, 8: 30–41, 2011.
11.
BurkhoffD, MaurerMS, and PackerM. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function?. Circulation, 107: 656–658, 2003.
12.
ChanJY and ChanSH. Activation of endogenous antioxidants as a common therapeutic strategy against cancer, neurodegeneration and cardiovascular diseases: a lesson learnt from DJ-1. Pharmacol Ther, 156: 69–74, 2015.
13.
ChoHY, MarzecJ, and KleebergerSR. Functional polymorphisms in Nrf2: implications for human disease. Free Radic Biol Med, 88: 362–372, 2015.
14.
CohnJN, FerrariR, and SharpeN. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 35: 569–582, 2000.
15.
CookNR, AlbertCM, GazianoJM, ZaharrisE, MacFadyenJ, DanielsonE, BuringJE, and MansonJE. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med, 167: 1610–1618, 2007.
16.
DhallaNS, TemsahRM, and NetticadanT. Role of oxidative stress in cardiovascular diseases. J Hypertens, 18: 655–673, 2000.
17.
EgglerAL, SmallE, HanninkM, and MesecarAD. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. Biochem J, 422: 171–180, 2009.
18.
GounderSS, KannanS, DevadossD, MillerCJ, WhiteheadKJ, OdelbergSJ, FirpoMA, Paine RIII, HoidalJR, AbelED, and RajasekaranNS. Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training. PLoS One, 7: e45697, 2012.
19.
GriffithOW and MeisterA. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). 254: 755, 8–7560, 1979.
20.
HariharanN, ZhaiP, and SadoshimaJ. Oxidative stress stimulates autophagic flux during ischemia/reperfusion. Antioxid Redox Signal, 14: 2179–2190, 2011.
21.
HuppkeP, WeissbachS, ChurchJA, SchnurR, KrusenM, Dreha-KulaczewskiS, Kuhn-VeltenWN, WolfA, HuppkeB, MillanF, BegtrupA, AlmusafriF, ThieleH, AltmullerJ, NurnbergP, MullerM, and GartnerJ. Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder. Nat Commun, 8: 818, 2017.
22.
JainA, MårtenssonJ, StoleE, AuldPA, and MeisterA. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci U S A, 88: 1913–1917, 1991.
23.
JonesDP.Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol, 348: 93–112, 2002.
24.
JonesDP, CarlsonJL, SamiecPS, SternbergPJr., ModyVCJr., ReedRL, and BrownLA.Glutathione measurement in human plasma. Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta, 275: 175–184, 1998.
25.
JonesDP and LiangY. Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol Med, 47: 1329–1338, 2009.
KenslerTW, EgnerPA, AgyemanAS, VisvanathanK, GroopmanJD, ChenJ-G, ChenT-Y, FaheyJW, and TalalayP. Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem, 329: 163–177, 2013.
28.
KlapholzM, MaurerM, LoweAM, MessineoF, MeisnerJS, MitchellJ, KalmanJ, PhillipsRA, SteingartR, Brown JrEJ, BerkowitzR, MoskowitzR, SoniA, ManciniD, BijouR, SehhatK, VarshneyaN, KukinM, KatzSD, SleeperLA, and Le JemtelTH. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York heart failure registry. J Am Coll Cardiol, 43: 1432–1438, 2004.
29.
KobayashiA, KangMI, WataiY, TongKI, ShibataT, UchidaK, and YamamotoM. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol, 26: 221–229, 2006.
30.
Kris-EthertonPM, LichtensteinAH, HowardBV, SteinbergD, and WitztumJL. Antioxidant vitamin supplements and cardiovascular disease. Circulation, 110: 637–641, 2004.
31.
KwakMK and KenslerTW. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol, 244: 66–76, 2010.
32.
LeeJM, LiJ, JohnsonDA, SteinTD, KraftAD, CalkinsMJ, JakelRJ, and JohnsonJA. Nrf2, a multi-organ protector?. FASEB J, 19: 1061–1066, 2005.
33.
MartenssonJ, JainA, StoleE, FrayerW, AuldPA, and MeisterA. Inhibition of glutathione synthesis in the newborn rat: a model for endogenously produced oxidative stress. Proc Natl Acad Sci U S A, 88: 9360–9364, 1991.
34.
McGeeAM and BainesCP. Complement 1q-binding protein inhibits the mitochondrial permeability transition pore and protects against oxidative stress-induced death. Biochem J, 433: 119–125, 2011.
35.
MeisterA.Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther, 51: 155–194, 1991.
36.
MiljkovikLV and SpiroskaV. Heart failure with preserved ejection fraction—concept, pathophysiology, diagnosis and challenges for treatment. Open Access Maced J Med Sci, 3: 521–527, 2015.
37.
MoritaH, NagaiR, SeidmanJG, and SeidmanCE. The impact of genetic testing on hypertrophic cardiomyopathy and heart failure (As of 12072009 by HIRO). J Cardiovasc Transl Res, 3: 297–303, 2010.
38.
MuthusamyVR, KannanS, SadhaasivamK, GounderSS, DavidsonCJ, BoehemeC, HoidalJR, WangL, and RajasekaranNS. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic Biol Med, 52: 366–376, 2012.
39.
NaguehSF, AppletonCP, GillebertTC, MarinoPN, OhJK, SmisethOA, WaggonerAD, FlachskampfFA, PellikkaPA, and EvangelistaA. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr, 22: 107–133, 2009.
40.
NarasimhanM and RajasekaranNS. Reductive potential—a savior turns stressor in protein aggregation cardiomyopathy. Biochim Biophys Acta, 1852: 53–60, 2015.
41.
PalliyaguruDL, ChartoumpekisDV, WakabayashiN, SkokoJJ, YagishitaY, SinghSV, and KenslerTW. Withaferin A induces Nrf2-dependent protection against liver injury: role of Keap1-independent mechanisms. Free Radic Biol Med, 101: 116–128, 2016.
42.
QuilesJM, NarasimhanM, MosbrugerT, ShanmugamG, CrossmanD, and RajasekaranNS. Identification of transcriptome signature for myocardial reductive stress. Redox Biol, 13: 568–580, 2017.
43.
RajasekaranNS, ConnellP, ChristiansES, YanLJ, TaylorRP, OroszA, ZhangXQ, StevensonTJ, PeshockRM, LeopoldJA, BarryWH, LoscalzoJ, OdelbergSJ, and BenjaminIJ. Human alpha B-crystallin mutation causes oxido-reductive stress and protein aggregation cardiomyopathy in mice. Cell, 130: 427–439, 2007.
44.
RajasekaranNS, DevarajNS, and DevarajH. Modulation of rat erythrocyte antioxidant defense system by buthionine sulfoximine and its reversal by glutathione monoester therapy. Biochim Biophys Acta, 1688: 121–129, 2004.
45.
RajasekaranNS, FirpoMA, MilashBA, WeissRB, and BenjaminIJ. Global expression profiling identifies a novel biosignature for protein aggregation R120GCryAB cardiomyopathy in mice. Physiol Genomics, 35: 165–172, 2008.
46.
RajasekaranNS, SathyanarayananS, DevarajNS, and DevarajH. Chronic depletion of glutathione (GSH) and minimal modification of LDL in vivo: its prevention by glutathione mono ester (GME) therapy. Biochim Biophys Acta, 1741: 103–112, 2005.
47.
RajasekaranNS, VaradharajS, KhanderaoGD, DavidsonCJ, KannanS, FirpoMA, ZweierJL, and BenjaminIJ. Sustained activation of nuclear erythroid 2-related factor 2/antioxidant response element signaling promotes reductive stress in the human mutant protein aggregation cardiomyopathy in mice. Antioxid Redox Signal, 14: 957–971, 2011.
48.
Roma-RodriguesC and FernandesAR. Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Appl Clin Genet, 7: 195–208, 2014.
49.
SantosCX, RazaS, and ShahAM. Redox signaling in the cardiomyocyte: from physiology to failure. Int J Biochem Cell Biol, 74: 145–151, 2016.
50.
SchnabelR and BlankenbergS. Oxidative stress in cardiovascular disease: successful translation from bench to bedside?. Circulation, 116: 1338–1340, 2007.
51.
SenCK and RoyS. Relief from a heavy heart: redox-sensitive NF-kappaB as a therapeutic target in managing cardiac hypertrophy. Am J Physiol Heart Circ Physiol, 289: H17–H19, 2005.
52.
ShanmugamG, NarasimhanM, ConleyRL, SairamT, KumarA, MasonRP, SankaranR, HoidalJR, and RajasekaranNS.Chronic endurance exercise impairs cardiac structure and function in middle-aged mice with impaired Nrf2 signaling. Front Physiol, 8, 2017.
53.
ShanmugamG, NarasimhanM, TamowskiS, Darley-UsmarV, and RajasekaranNS. Constitutive activation of Nrf2 induces a stable reductive state in the mouse myocardium. Redox Biol, 12: 937–945, 2017.
54.
ShelarSB, NarasimhanM, ShanmugamG, LitovskySH, GounderSS, KaranG, ArulvasuC, KenslerTW, HoidalJR, Darley-UsmarVM, and RajasekaranNS. Disruption of nuclear factor (erythroid-derived-2)-like 2 antioxidant signaling: a mechanism for impaired activation of stem cells and delayed regeneration of skeletal muscle. FASEB J, 30: 1865–1879, 2016.
55.
SmyrniasI, ZhangX, ZhangM, MurrayTV, BrandesRP, SchroderK, BrewerAC, and ShahAM. Nicotinamide adenine dinucleotide phosphate oxidase-4-dependent upregulation of nuclear factor erythroid-derived 2-like 2 protects the heart during chronic pressure overload. Hypertension, 65: 547–553, 2015.
56.
SorrientoD, De LucaN, TrimarcoB, and IaccarinoG. The antioxidant therapy: new insights in the treatment of hypertension. Front Physiol, 9: 258, 2018.
57.
StevenS, MunzelT, and DaiberA. Exploiting the pleiotropic antioxidant effects of established drugs in cardiovascular disease. Int J Mol Sci, 16: 18185–18223, 2015.
58.
TaguchiK, MotohashiH, and YamamotoM. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells, 16: 123–140, 2011.
59.
TribbleDL.AHA Science Advisory. Antioxidant consumption and risk of coronary heart disease: emphasison vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation, 99: 591–595, 1999.
60.
TsutsuiH, KinugawaS, and MatsushimaS. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol, 301: H2181–H2190, 2011.
61.
XinM, OlsonEN, and Bassel-DubyR. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. Nat Rev Mol Cell Biol, 14: 529–541, 2013.
62.
YamamotoM, KenslerTW, and MotohashiH. The KEAP1-NRF2 System: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol Rev, 98: 1169–1203, 2018.
63.
YounJY, SiuKL, LobHE, ItaniH, HarrisonDG, and CaiH. Role of vascular oxidative stress in obesity and metabolic syndrome. Diabetes, 63: 2344–2355, 2014.
64.
YounJY, ZhangJ, ZhangY, ChenH, LiuD, PingP, WeissJN, and CaiH. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol, 62: 72–79, 2013.
65.
ZoueinFA, de Castro BrásLE, da CostaDV, LindseyML, KurdiM, and BoozGW. Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol, 62: 13–21, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
